{
    "clinical_study": {
        "@rank": "95623", 
        "arm_group": [
            {
                "arm_group_label": "MSC plus NSAID", 
                "arm_group_type": "Experimental", 
                "description": "human mesenchymal stem cells:1*10^4-6 cells /Kg , IV (in the vein) on day 1 of each 14-60 day cycle,1-6 times treatment, plus non-steroid anti-inflammatory drugs (NSAID: \"celecoxib\", \"Celebrex\u00ae\" 0.2g Bid(twice a day),PO (Per Os).\nDuration of treatment:24 weeks for follow up. collect peripheral blood (PBMCs and serums)of those patients at baseline and every 4 weeks for basic study after they signed informed consent."
            }, 
            {
                "arm_group_label": "NSAID", 
                "arm_group_type": "Experimental", 
                "description": "non-steroid anti-inflammatory drugs (NSAID: \"celecoxib\", \"Celebrex\u00ae\" 0.2g Bid(twice a day),PO (Per Os);a total of 24 weeks for follow up;collect peripheral blood (PBMCs and serums)of those patients at baseline and every 4 weeks for basic study after they signed informed consent."
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators will recruit active ankylosing spondylitis patients for injection\n      treatment of Human Mesenchymal Stem Cells (a prospective, open-label, masculine medicine\n      controlled(NSAIDs), clinical trial), and collect their Peripheral Blood Lymphocyte (PBMCs)\n      and sera before and after the treatment of 24 weeks to test the gene expression profiles and\n      study related pathogenesis of  AS"
        }, 
        "brief_title": "A Molecule Basic Study of Early Warning for New Pathogenic Risk of Ankylosing Spondylitis", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Ankylosing Spondylitis", 
        "condition_browse": {
            "mesh_term": [
                "Spondylitis", 
                "Spondylitis, Ankylosing"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Aged from 16-65 years, sign the Informed Consent\n\n          2. Fulfill 1984 modified NewYork classification criteria for AS\n\n          3. Have an active refractory disease defined by a score \u226540 on the Bath AS Disease\n             Activity Index (BASDAI) (0-100) despite optimal non-steroidal anti-inflammatory drug\n             (NSAID) treatment.\n\n          4. Commitment to contraceptive for woman\n\n        Exclusion Criteria:\n\n          1. Completely stiff spine\n\n          2. Received spinal or joint surgery within 2 months\n\n          3. Received anti-TNF therapy within 3 months\n\n          4. History of the listed diseases: heart failure, Multiple sclerosis, severe chronic\n             obstructive pulmonary disease, frequent infections, lymphoma or other cancers,\n             tuberculosis\n\n          5. Female of pregnancy or breast feeding\n\n          6. Hb\u2264 9g/dl for male or Hb \u2264 8.5 g/dl for male, ALT/AST\u22652folds of upper level normal\n             range, Creatine\u2265120mol/L(\u22641.4mg/dl)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01709656", 
            "org_study_id": "[2012]2-31"
        }, 
        "intervention": [
            {
                "arm_group_label": "MSC plus NSAID", 
                "description": "human mesenchymal stem cells,1*10^4-6 cells /Kg , IV (in the vein) on day 1 of each 14-60 day cycle,1-6 times treatment.\na total of 24 weeks for follow up.", 
                "intervention_name": "MSC", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "MSC plus NSAID", 
                    "NSAID"
                ], 
                "description": "non-steroid anti-inflammatory drugs (NSAID):\"celecoxib\", \"Celebrex\u00ae\" 0.2g Bid(twice a day),PO (Per Os);a total of 24 weeks for follow up", 
                "intervention_name": "\"celecoxib\", \"Celebrex\u00ae\"", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Celecoxib", 
                "Anti-Inflammatory Agents", 
                "Anti-Inflammatory Agents, Non-Steroidal"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "contact": {
                "email": "gujieruo@163.com", 
                "last_name": "Jieruo Gu, M.D.", 
                "phone": "+8620-85252055"
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong"
                }, 
                "name": "Department of Rheumatology, the Third Affiliated Hospital of Sun Yat-sen University"
            }, 
            "investigator": {
                "last_name": "Jieruo Gu, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Molecule Basic Study of Early Warning for New Pathogenic Risk of Ankylosing Spondylitis", 
        "overall_contact": {
            "email": "gujieruo@163.com", 
            "last_name": "Jieruo Gu, M.D.", 
            "phone": "+8620-85252055"
        }, 
        "overall_official": {
            "affiliation": "Department of Rheumatology , Third Affiliated Hospital of Sun Yat-sen University", 
            "last_name": "Jieruo Gu, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "the proportion of patients which disease activity reaches ASAS(assessment in ankylosing Spondylitis)20 remission criteria", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01709656"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-sen University", 
            "investigator_full_name": "Gu Jieruo", 
            "investigator_title": "Department of Rheumatology, Third Affiliated Hospital of Sun Yat-sen University", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "BASDAI score comparing to baseline", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "BASFI score comparing to baseline", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }
        ], 
        "source": "Sun Yat-sen University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sun Yat-sen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}